<DOC>
	<DOCNO>NCT00558285</DOCNO>
	<brief_summary>An investigational inhalation product ( QVA149 ) treatment patient Chronic Obstructive Pulmonary Disease ( COPD ) develop . This 14 day study investigate effect heart rate cardiovascular effect ensure product safe .</brief_summary>
	<brief_title>Safety Tolerability QVA149 ( Indacaterol/Glycopyrrolate ) Compared Placebo Indacaterol Patients With Moderate Severe Stable Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Consented male female adult age ≥40 year Moderate severe stable Chronic Obstructive Pulmonary Disease ( COPD ) accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines ( 2006 ) Patients smoke history least 10 pack year Patients postbronchodilator Forced Expiratory Volume one second ( FEV1 ) ≥30 % &lt; 80 % predict normal postbronchodilator FEV1/Forced vital capacity ( FVC ) &lt; 0.70 Visit 1 Visit 3 Pregnant nursing ( lactate ) woman Patients require long term oxygen therapy ( &gt; 15 hour day ) daily basis chronic hypoxemia , hospitalize visited emergency room COPD exacerbation 6 week prior screen ( Visit 1 ) screening period Patients respiratory tract infection within 6 week Visit 1 screen Concomitant pulmonary disease , pulmonary tuberculosis ( TB ) ( unless chest xray confirms longer active ) clinically significant bronchiectasis Any history asthma Patients clinically relevant lab abnormality / condition ( limit ) long term prednisone therapy , unstable ischemic heart disease , leave ventricular failure , history myocardial infarction , arrhythmia ( exclude stable atrial fibrillation [ AF ] ) , uncontrolled hypertension , narrowangle glaucoma , symptomatic prostatic hyperplasia bladderneck obstruction moderate severe renal impairment , uncontrolled hypo hyperthyroidism , hypokalemia , hyperadrenergic state condition might compromise patient safety compliance , interfere evaluation , preclude completion study Patients history cardiac failure , life threaten arrhythmia ( screen Holter ) acute ischemic change ( screen ECG ) Patients history long QT syndrome whose QTc ( Fridericia method ) interval measure screening ( Visit 1 ) prolong ( &gt; 450 m male &gt; 470 female ) History malignancy organ system , treat untreated within past 5 year Uncontrolled Type I / Type II Diabetes blood glucose outside normal range Hemoglobin A1C ( HbA1c ) &gt; 8.0 % total hemoglobin measure Visit 1 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Indacaterol</keyword>
	<keyword>QVA149</keyword>
</DOC>